Q4 2024 Earnings Call Transcript March 17, 2025 Quanterix Corporation misses on earnings expectations. Reported EPS is $-0.3 ...

Four serum neurofilament light chain tests show high accuracy in diagnosing ALS and predicting its progression, new research suggests.

High-sensitivity immunoassay firm Quanterix, for instance, applied its Simoa technology to measuring blood-based neurology markers like neurofilament light chain (NfL) as well as Alzheimer's-linked ...

NfL was assessed using the ultrasensitive Simoa and microfluidic Ella platforms and with Lumipulse and Elecsys assays, ...

NfL was assessed using the ultrasensitive Simoa and microfluidic Ella platforms and with Lumipulse and Elecsys assays, recently set up on clinical-grade platforms. Serum GFAP and pTau181 were also ...